Page last updated: 2024-08-21

oxazoles and c-peptide

oxazoles has been researched along with c-peptide in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (33.33)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cappelletti, G; Cavagnini, F; Dubini, A; Invitti, C; Pinto, M; Polli, EE	1
Belder, R; Chen, S; Cheng, PT; Devasthale, P; Egan, D; Farrelly, D; French, M; Gu, L; Hariharan, N; Harrity, T; Janovitz, E; Kunselman, L; Peters, A; Ponticiello, R; Staal, A; Swartz, J; Taylor, S; Tozzo, E; Welzel, G; Whaley, J; Zebo, R	1
Fiedorek, FT; Rubin, CJ; Viraswami-Appanna, K	1

Trials

2 trial(s) available for oxazoles and c-peptide

Article	Year
Effects of gamma aminobutyric acid (GABA) and muscimol on endocrine pancreatic function in man. Metabolism: clinical and experimental, 1982, Volume: 31, Issue:1 Topics: Adolescent; Adult; Blood Glucose; C-Peptide; Female; gamma-Aminobutyric Acid; Glucagon; Humans; Insulin; Islets of Langerhans; Male; Middle Aged; Muscimol; Oxazoles	1982
Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes. Diabetes & vascular disease research, 2009, Volume: 6, Issue:3 Topics: Biomarkers; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Edema; Female; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Time Factors; Treatment Outcome; Weight Gain	2009

Article

Year

Effects of gamma aminobutyric acid (GABA) and muscimol on endocrine pancreatic function in man.

Metabolism: clinical and experimental, 1982, Volume: 31, Issue:1

Topics: Adolescent; Adult; Blood Glucose; C-Peptide; Female; gamma-Aminobutyric Acid; Glucagon; Humans; Insulin; Islets of Langerhans; Male; Middle Aged; Muscimol; Oxazoles

1982

Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes.

Diabetes & vascular disease research, 2009, Volume: 6, Issue:3

Topics: Biomarkers; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Edema; Female; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Time Factors; Treatment Outcome; Weight Gain

2009

Other Studies

1 other study(ies) available for oxazoles and c-peptide

Article	Year
The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice. The Journal of pharmacology and experimental therapeutics, 2007, Volume: 321, Issue:1 Topics: Animals; Body Weight; C-Peptide; Diabetes Mellitus, Experimental; Disease Progression; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Glycated Hemoglobin; Glycine; Hypoglycemic Agents; Insulin; Islets of Langerhans; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Oxazoles; Pancreas; PPAR alpha; PPAR gamma; Triglycerides	2007

Article

Year

The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice.

The Journal of pharmacology and experimental therapeutics, 2007, Volume: 321, Issue:1

Topics: Animals; Body Weight; C-Peptide; Diabetes Mellitus, Experimental; Disease Progression; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Glycated Hemoglobin; Glycine; Hypoglycemic Agents; Insulin; Islets of Langerhans; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Oxazoles; Pancreas; PPAR alpha; PPAR gamma; Triglycerides

2007